Nevro Corp. (NVRO)
USD 3.74
(-7.65%)
USD 3.74
(-7.65%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 425.17 Million USD | 4.63% |
| 2022 | 406.36 Million USD | 5.03% |
| 2021 | 386.9 Million USD | 6.87% |
| 2020 | 362.04 Million USD | -7.23% |
| 2019 | 390.25 Million USD | 0.77% |
| 2018 | 387.28 Million USD | 18.56% |
| 2017 | 326.67 Million USD | 42.96% |
| 2016 | 228.5 Million USD | 228.28% |
| 2015 | 69.6 Million USD | 113.69% |
| 2014 | 32.57 Million USD | 38.61% |
| 2013 | 23.5 Million USD | 29.48% |
| 2012 | 18.15 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 104.16 Million USD | 2.22% |
| 2024 Q1 | 101.89 Million USD | -12.29% |
| 2023 Q4 | 116.17 Million USD | 11.86% |
| 2023 Q3 | 103.86 Million USD | -4.55% |
| 2023 FY | 425.17 Million USD | 4.63% |
| 2023 Q1 | 96.32 Million USD | -15.39% |
| 2023 Q2 | 108.8 Million USD | 12.96% |
| 2022 Q4 | 113.84 Million USD | 13.32% |
| 2022 Q2 | 104.21 Million USD | 18.64% |
| 2022 Q1 | 87.84 Million USD | -14.52% |
| 2022 FY | 406.36 Million USD | 5.03% |
| 2022 Q3 | 100.46 Million USD | -3.6% |
| 2021 Q2 | 102.33 Million USD | 15.48% |
| 2021 FY | 386.9 Million USD | 6.87% |
| 2021 Q3 | 93.2 Million USD | -8.92% |
| 2021 Q1 | 88.61 Million USD | -19.25% |
| 2021 Q4 | 102.76 Million USD | 10.25% |
| 2020 Q4 | 109.73 Million USD | 1.17% |
| 2020 Q3 | 108.46 Million USD | 92.34% |
| 2020 Q2 | 56.39 Million USD | -35.53% |
| 2020 FY | 362.04 Million USD | -7.23% |
| 2020 Q1 | 87.46 Million USD | -23.53% |
| 2019 Q3 | 100.16 Million USD | 7.04% |
| 2019 Q2 | 93.57 Million USD | 13.91% |
| 2019 Q1 | 82.14 Million USD | -23.9% |
| 2019 FY | 390.25 Million USD | 0.77% |
| 2019 Q4 | 114.37 Million USD | 14.19% |
| 2018 Q2 | 96.08 Million USD | 9.64% |
| 2018 Q3 | 95.63 Million USD | -0.47% |
| 2018 Q4 | 107.94 Million USD | 12.88% |
| 2018 FY | 387.28 Million USD | 18.56% |
| 2018 Q1 | 87.63 Million USD | -10.54% |
| 2017 Q2 | 78.01 Million USD | 13.99% |
| 2017 FY | 326.67 Million USD | 42.96% |
| 2017 Q4 | 97.96 Million USD | 19.1% |
| 2017 Q3 | 82.25 Million USD | 5.43% |
| 2017 Q1 | 68.43 Million USD | -2.97% |
| 2016 Q1 | 41.65 Million USD | 25.74% |
| 2016 Q2 | 55.4 Million USD | 33.01% |
| 2016 Q3 | 60.92 Million USD | 9.97% |
| 2016 FY | 228.5 Million USD | 228.28% |
| 2016 Q4 | 70.53 Million USD | 15.77% |
| 2015 Q4 | 33.12 Million USD | 115.06% |
| 2015 Q3 | 15.4 Million USD | 34.89% |
| 2015 Q2 | 11.41 Million USD | 18.17% |
| 2015 Q1 | 9.66 Million USD | -0.55% |
| 2015 FY | 69.6 Million USD | 113.69% |
| 2014 Q1 | 6.66 Million USD | 7.55% |
| 2014 FY | 32.57 Million USD | 38.61% |
| 2014 Q4 | 9.71 Million USD | 12.08% |
| 2014 Q3 | 8.66 Million USD | 15.17% |
| 2014 Q2 | 7.52 Million USD | 12.94% |
| 2013 Q3 | 6.19 Million USD | 8.76% |
| 2013 FY | 23.5 Million USD | 29.48% |
| 2013 Q4 | 6.19 Million USD | -0.03% |
| 2013 Q1 | 5.4 Million USD | 0.0% |
| 2013 Q2 | 5.69 Million USD | 5.4% |
| 2012 FY | 18.15 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 98.94% |
| Allurion Technologies Inc. | 53.46 Million USD | -695.208% |
| Artivion, Inc. | 354 Million USD | -20.104% |
| Avanos Medical, Inc. | 673.3 Million USD | 36.852% |
| Butterfly Network, Inc. | 65.9 Million USD | -545.181% |
| Butterfly Network, Inc. | 65.9 Million USD | -545.181% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 84.083% |
| Boston Scientific Corporation | 14.24 Billion USD | 97.014% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -5884.994% |
| CONMED Corporation | 1.24 Billion USD | 65.738% |
| Edwards Lifesciences Corporation | 6 Billion USD | 92.919% |
| Paragon 28, Inc. | 216.38 Million USD | -96.486% |
| Glaukos Corporation | 314.71 Million USD | -35.1% |
| Globus Medical, Inc. | 1.56 Billion USD | 72.893% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | 31.95% |
| Integer Holdings Corporation | 1.59 Billion USD | 73.371% |
| Medtronic plc | 32.36 Billion USD | 98.686% |
| Owlet, Inc. | 54.01 Million USD | -687.213% |
| Penumbra, Inc. | 1.05 Billion USD | 59.833% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 92.338% |
| Sonendo, Inc. | 43.86 Million USD | -869.278% |
| STERIS plc | 5.13 Billion USD | 91.726% |
| Stryker Corporation | 20.49 Billion USD | 97.926% |
| Vapotherm, Inc. | 68.66 Million USD | -519.164% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 94.25% |